Información del artículo
Abstract
Anti-TNFα agents represent an outstanding advance in the symptomatic control of patients with ankylosing spondylitis presenting an inadequate response to non-steroidal anti-inflammatory drugs. Anti-TNFα antagonists have demonstrated efficacy and safety in the long-term but continuous therapy is needed for an adequate control of symptoms. After the failure to a first anti-TNFα agent, the use of a second TNFα antagonist seems to be effective and safe. Despite the fast and continuous suppression of bone inflammation, demonstrated by magnetic resonance imaging, the beneficial effect of treatment with TNFα antagonists on the radiological evolution has not been demonstrated to date in ankylosing spondylitis. It seems that insights into new therapeutic molecular targets implicated in the process of ossification are needed.
Keywords:
Ankylosing spondylitis
Anti-TNFα therapy
Structural damage
Resumen
Los agentes anti-TNFα han representado un notable avance en el control sintomático de los pacientes con espondilitis anquilosante y respuesta inadecuada a AINE. Los antagonistas del TNFα son eficaces y seguros a largo plazo pero es necesario su uso continuado para un adecuado control sintomático. Tras el fracaso a uno de ellos, el uso de un segundo agente anti-TNFα parece ser eficaz y seguro. Aún no se ha demostrado un efecto beneficioso del tratamiento con antagonistas del TNFα sobre la evolución radiológica en la espondilitis anquilosante, a pesar de la desaparición rápida y mantenida de la inflamación ósea, evidenciada mediante RM. Parece necesario explorar nuevas dianas moleculares implicadas en el proceso de osificación.
Palabras clave:
Espondilitis anquilosante
Terapia anti-TNFα
Daño estructural
El Texto completo está disponible en PDF
References
[1.]
J. Braun, M. Bollow, L. Neure, E. Seipelt, F. Seyrekbasan, H. Herbst, et al.
Use of inmunohistologic and in situ hibridization tecniques in the examination of the sacroiliac joints from patients with ankylosing spondylitis.
Arthritis Rheum, 38 (1995), pp. 499-505
[2.]
D. Van der Heijde, B. Dijkmans, P. Geusens, J. Sieper, K. De Woody, P. Williamson, et al.
Efficacy and safety of infliximab in patients with ankylosing spondylitis.
Arthritis Rheum., 52 (2005), pp. 582-591
[3.]
A. Calin, B.A.C. Dijkmans, P. Emery, M. Hakala, J. Kaldenj, M. Leirisalo-Repo, et al.
Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis.
Ann Rheum Dis., 63 (2004), pp. 1594-1600
[4.]
D. Van der Heijde, A. Kivitz, M.H. Schiff, J. Sieper, B.A.C. Dijkmans, J. Braun, et al.
Efficacy and safety of adalimumab in patients with ankylosing spondylitis.
Arthritis Rheum., 54 (2006), pp. 2136-2146
[5.]
R. Inman, J.C. Davis Jr., D. Van der Heijde, L. Diezman, J. Sieper, S. Kim, et al.
Efficacy and safety of golimumab in patients with ankylosing spondylitis.
Arthritis Rheum., 58 (2008), pp. 3402-3412
[6.]
J. Braun, N. McHugh, A. Singh, J.S. Wajdula, R. Sato.
Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50mg once-weekly and 25mg twice-weekly.
Rheumatology (Oxford)., 46 (2007), pp. 999-1004
[7.]
J. Braun, X. Baraliakos, J. Listing, C. Fritz, R. Alten, G. Burmester, et al.
Persistent clinical efficacy and safety of anti-tumour necrosis factor a therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response.
Ann Rheum Dis., 67 (2008), pp. 340-345
[8.]
C. Davis Jr., D. Van der Heijde, J. Braun, M. Dougados, D.O. Clegg, A.J. Kivitz, et al.
Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis.
Ann Rheum Dis., 67 (2008), pp. 346-352
[9.]
D. Van der Heijde, M.H. Schiff, J. Sieper, A. Kivitz, R.L. Wong, H. Kupper, et al.
Adalimumab effectiveness for the treatment of ankylosing spondylitisis maintained for up to 2 years: long-term results from the ATLAS trial.
Ann Rheum Dis,, (2008),
[10.]
X. Baraliakos, J. Listing, C. Fritz, R. Alten, G. Burmester, A. Krause, et al.
Persistent clinical efficacy and safety of infliximab in patients with ankylosing spondylitis over 7 years. Evidence for different response to anti-TNFα therapy.
Ann Rheum Dis., 67 (2008), pp. 375
[11.]
L. Carmona, J.J. Gomez-Reino, BIOBADASER Group.
Survival of TNF antagonists in spondylarthritisis better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER.
Arthritis Res Ther., 8 (2006), pp. R72
[12.]
X. Baraliakos, J. Listing, J. Brandt, M. Rudwaleit, J. Sieper, J. Braun.
Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab.
Arthritis Research & Therapy., 7 (2005), pp. 439-444
[13.]
X. Baraliakos, J. Listing, M. Rudwaleit, J. Brandt, R. Alten, G. Burmester, et al.
Safety and efficacy of readministration of infliximab after longterm continuous therapy and with drawal in patients with ankylosing spondylitis.
J Rheumatology., 34 (2007), pp. 510-515
[14.]
J. Brandt, J. Listing, H. Haibel, H. Sörensen, A. Schwebig, M. Rudwaleit, et al.
Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis.
Rheumatology., 44 (2005), pp. 342-348
[15.]
M. Breban, P. Ravaud, P. Claudepierre, G. Baron, Y.D. Henry, C. Hudry, et al.
Maintenance of infliximab treatment in ankylosing spondylitis.
Arthritis Rheum., 58 (2008), pp. 88-97
[16.]
F. Conti, F. Ceccarelli, E. Marocchi, L. Magrini, F.R. Spinelli, A. Spadaro, et al.
Switching tumour necrosis factor a antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.
Ann Rheum Dis., 66 (2007), pp. 1393-1397
[17.]
C. Delaunay, V. Farrenq, A. Marini-Portugal, J.D. Cohen, X. Chevalier, P. Claudepierre, et al.
Infliximabto etanercepts witch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data.
J Rheumatology., 32 (2005), pp. 2183-2185
[18.]
L.C. Coates, L.S. Cawkwell, N.W.F. Ng, A.N. Bennett, D.J. Bryer, A.D. Fraser, et al.
Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis.
Rheumatology., 47 (2008), pp. 897-900
[19.]
N. Barkham, H.I. Keen, L.C. Coates, P. O’Connor, E.M.A. Hensor, A.D. Fraser, et al.
A randomized controlled trial of infliximab shows clinical and MRI efficacy in HLA B27 positive very early ankylosing spondylitis.
Ann Rheum Dis., 67 (2008), pp. 382
[20.]
A.L. Amtenbrink, H. Haibel, M. Rudwaleit, J. Listing, F. Heldmann, R. Wong, et al.
Efficacy of adalimumab in the treatment of patients with axial spondyloarthritis (SPA) and no radiographic sacroilitis: continuous adalimumab therapy is necessary to prevent relapses after treatment with drawal.
Ann Rheum Dis., 67 (2008), pp. 373
[21.]
R. Landewé, M. Dougados, H. Mielants, H. Van der Tempel, D. Van der Heijde.
Physical function in ankylosing spondylitis is independently determined by both disease activity and radiographic damage of the spine.
Ann Rheum Dis,, (2008),
[22.]
X. Baraliakos, J. Davis, W. Tsuji, J. Braun.
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor a receptor fusion protein etanercept.
Arthritis Rheum., 52 (2005), pp. 1216-1223
[23.]
W.P. Maksymowych, R.D. Inman, D. Salonen, S.S. Dhillon, M. Williams, M. Stone, et al.
Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis.
Arthritis Rheum., 53 (2005), pp. 703-709
[24.]
X. Baraliakos, J. Davis, W. Tsuji, J. Braun.
Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor apha receptor fusion protein etanercept.
Arthritis Rheum., 52 (2005), pp. 1216-1223
[25.]
J. Sieper, X. Baraliakos, J. Listing, J. Brandt, H. Haibel, M. Rudwaleit, et al.
Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab.
Rheumatology., 44 (2005), pp. 1525-1530
[26.]
X. Baraliakos, J. Listing, M. Rudwaleit, J. Sieper, J. Braun.
The relationship between inflammation and new bone formation in patients with ankylosing spondylitis.
Arthritis Res Ther., 10 (2008), pp. R104
[27.]
X. Baraliakos, J. Listing, M. Rudwaleit, H. Haibel, J. Brandt, J. Sieper, et al.
Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes.
Ann Rheum Dis., 66 (2007), pp. 910-915
[28.]
D. Van der Heijde, R. Landewé, X. Baraliakos, H. Houben, A. Van Tubergen, P. Williamson, et al.
Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
Arthritis Rheum., 58 (2008), pp. 3063-3070
[29.]
D. Van der Heijde, R. Landewé, S. Einstein, P. Ory, D. Vosse, L. Ni, et al.
Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.
Arthritis Rheum., 58 (2008), pp. 1324-1331
[30.]
D. Diarra, M. Stolina, K. Polzer, J. Zwerina, M.S. Ominsky, D. Dwyer, et al.
Dickkopf-1 is a master regulator of joint remodeling.
Nat Med., 13 (2007), pp. 156-163
[31.]
R.J. Lories, I. Derese, C. De Bari, F.P. Luyten.
Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondyl arthritis.
Arthritis Rheum., 56 (2007), pp. 489-497
[32.]
A. Wanders, D. Van der Heijde, R. Landewé, J.M. Béhier, A. Calin, I. Olivieri, et al.
Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis.
Arthritis Rheum., 52 (2005), pp. 1756-1765
[33.]
X. Zhang, E.M. Schwarz, D.A. Young, J.E. Puzas, R.N. Rosier, R.J. O’keefe.
Cyclooxygenase-2 regulates mesenchymal cell differentiation into the osteoblast lineage and is critically involved in bone repair.
J Clin Invest, 109 (2002), pp. 1405-1415
[34.]
K. Ijiri, S. Matsunaga, T. Fukuda, T. Shimizu.
Indomethacin inhibition of ossification induced by direct current stimulation.
J Orthop Res., 13 (1995), pp. 123-131
[35.]
B. Neal, A. Rodgers, L. Dunn, M. Fransen.
Non-steroidal anti-inflammatorydrugs for preventing heterotopic bone formation after hiparthroplasty.
Cochrane Database SystRev., 3 (2000), pp. CD001160
Copyright © 2011. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
